Tavotek Biotherapeutics

?? Join us at the Lotte Biologics Technical Development Forum! ?? We're excited to announce that Mark Chiu, Ph.D., President and Chief Scientific Officer of Tavotek Biotherapeutics, will be presenting at the upcoming Technical Development Forum hosted by LOTTE BIOLOGICS. ?? Date & Time: Wednesday, August 28, 2024, at 9 a.m. EST / 9 p.m. KST ?? Location: Building 35 Auditorium

We are proud to share our Phase 1 study results of TAVO101, an anti-TSLP antibody for treating allergic inflammatory conditions, has been published in the Journal of Clinical Pharmacology! Check out the full article here: https://lnkd.in/eq2NFVJx #Tavotek #ACCP

?? Dr. Mark Chiu, PhD, will present a revolutionary approach to tackling EGFR inhibitor-resistant NSCLC using EGFR x cMET bispecific antibodies. Discover: ?? A process for selecting lead candidates with high functional activity. ?? In vitro cell-based assays for critical endpoint determination. ?? Strategies for designing bispecific formats targeting multiple therapeutic pathways. Don't miss this opportunity to delve into cutting-edge cancer treatment research and engage with our expert panelist during the live Q&A session. Register now and be a part of the future of oncology! ?? #CancerResearch #LungCancer #BispecificAntibodies #OncologyInnovation #Webinar https://lnkd.in/gFDTKbJ8

Tavotek and David Brooks will be attending BIO 2024 in San Diego from June 3-6! Come chat with us to explore our latest biotherapeutic innovations. #BIO2024 #Tavotek Setup a meeting with us here --> https://lnkd.in/gcQVGJd4

We are thrilled to be featured in the latest GEN article on multispecific antibodies. Check out the full article to learn more about how we're making strides in the fight against cancer. https://lnkd.in/eeZ3N252

Thrilled to reflect on the insights gained from the BIONNOVA Beijing Innovation Forum 2024 and Festival of Biologics 2024, attended by our senior leadership. These conferences were invaluable for building global networks and sharing advancements in biotechnology. Excited to apply these innovative learnings to propel Tavotek forward. #Biotech #Innovation #Leadership #Networking #BIONNOVABeijing2024 #FestivalOfBiologics2024

?? Exciting News! Tavotek Biotherapeutics is thrilled to announce approval from Australia for our groundbreaking Phase 2 Trial featuring TAVO101, a best-in-class TSLP monoclonal antibody, targeting Severe Atopic Dermatitis! ? ?? Australia, known for its commitment to healthcare innovation, will be the starting point for our Phase 2 Trial. Tavotek Biotherapeutics is pioneering meaningful contributions to the field of biotherapeutics by providing relief and improving the quality of life for those affected by severe atopic dermatitis. ? ??TAVO101 is a long-lasting TSLP antibody engineered with extended dosing ability for patient convenience. This trial is set to commence dosing in Q1 2024, this milestone underscores our dedication to advancing treatment options for patients globally. ? We extend our heartfelt appreciation to the entire Tavotek team and our partners at HiRO - Harvest Integrated Research Organization, whose unwavering commitment has brought us to this pivotal moment. Together, we are pushing the boundaries of innovation to address the unique challenges posed by persistent health challenges. ? #Tavotek #Biotechnology #TSLP #BiologicTherapy #AtopicDermatitis #Eczema #Dermatology

??Tavotek Biotherapeutics is thrilled to highlight Dr. Chao Han's interview in Clinical Pharmacology and Therapeutics by American Society of Clinical Pharmacology and Therapeutics. Dr. Han spoke about his time spearheading groundbreaking work at Tavotek in delivering RNA-based therapeutics into tumor cells. ? ?? Professional Achievement: Tavotek's innovative techniques show promising data, such as addressing?"undruggable" intracellular targets in oncology. ? ?? Cutting-Edge Technology: Tavotek's focus on RNA-based therapeutics exhibit game-changer qualities in the quest for breakthrough oncology treatments. Congratulations to Dr. Han for being featured in ASCPT, we appreciate your thoughtful insights and skillful leadership! ?? Click here to read the full article: https://lnkd.in/e-xbwwyA #RNAtherapeutics #BiotechInnovation #OncologyBreakthroughs #UnmetMedicalNeeds #Tavotek

Tavotek Biotherapeutics is pleased to announce that our Chief Scientific Officer, Dr. Mark Chiu, will be showcased at the 23rd annual PepTalk Conference, happening from January 16-19, 2024, in San Diego, CA! His presentation is titled "1, 2, Bispecific Antibodies Do; 3, 4; Look Out for More; Driving Stronger Responses with Combinations of Bispecific Antibodies." This opportunity will delve into the future of biopharma, register now at CHI-peptalk.com! #PepTalkConference #BispecificAntibodies #PepTalk2024 #SanDiegoEvents #Tavotek